NCT02113319View on ClinicalTrials.gov

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2012

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

dasatinib

dasatinib 50 mg and 20 mg During one year

Trial Locations (1)

49 933

University Hospital, Angers

All Listed Sponsors
lead

University Hospital, Angers

OTHER_GOV

NCT02113319 - Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter